Is it time to stop treating subsets of DLBCL with R-CHOP?

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

Correlative data evaluating BCL6 protein expression and outcome in the US intergroup phase 3 randomized study of R-CHOP versus CHOP demonstrate that CHOP chemotherapy without rituximab is ineffective in BCL6-negative DLBCL.

Original languageEnglish (US)
Pages (from-to)4197-4198
Number of pages2
JournalBlood
Volume107
Issue number11
DOIs
StatePublished - Jun 1 2006

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Is it time to stop treating subsets of DLBCL with R-CHOP?'. Together they form a unique fingerprint.

  • Cite this